Interrelatedness between C-reactive protein and oxidized low-density lipoprotein

Clinical Chemistry and Laboratory Medicine

Volumn 53, Issue 1, 2015, Pages 29-34

  Obradovic, Milan M ^a   Trpkovic, Andreja ^a   Bajic, Vladan ^a   Soskic, Sanja ^a   Jovanovic, Aleksandra ^a   Stanimirovic, Julijana ^a   Panic, Milos ^b   Isenovic, Esma R ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Clinical Hospital Center Zemun   (Serbia)

Author keywords

C reactive protein (CRP); C reactive protein and oxidized low density lipoprotein (OxLDL) interrelatedness; oxidized low density lipoprotein

Indexed keywords

BETA2 GLYCOPROTEIN 1; C REACTIVE PROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; REACTIVE OXYGEN METABOLITE; LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPLEX FORMATION; CORRELATION ANALYSIS; ENDOTHELIUM CELL; FEMALE; HUMAN; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MALE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION; BLOOD; METABOLISM;

BETA 2-GLYCOPROTEIN I; C-REACTIVE PROTEIN; HUMANS; LIPOPROTEINS, LDL;

EID: 84916226347     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0590     Document Type: Review

References (88)

1. Marcovina SM, Crea F, Davignon J, Kaski JC, Koenig W, Landmesser U, et al. Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: A road to integration of complementary diagnostic tools. J Intern Med 2007;261:214-34.
2. Verhoye E, Langlois MR. Circulating oxidized low-density lipoprotein: A biomarker of atherosclerosis and cardiovascular risk? Clin Chem Lab Med 2009;47:128-37.
3. Steinberg D. The LDL modification hypothesis of atherogenesis: An update. J Lipid Res 2009;50(Suppl):S376-81.
4. Ansar W, Ghosh S. C-reactive protein and the biology of disease. Immunol Res 2013;56:131-42.
5. Moshage HJ, Roelofs HM, van Pelt JF, Hazenberg BP, van Leeuwen MA, Limburg PC, et al. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem Biophys Res Commun 1988;155:112-7.
6. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003;108:1930-2.
7. Thompson D, Pepys MB, Wood SP. The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 1999;7:169-77.
8. Eisenhardt SU, Thiele JR, Bannasch H, Stark GB, Peter K. C-reactive protein: How conformational changes influence inflammatory properties. Cell Cycle 2009;8:3885-92.
9. Calabro P, Golia E, Yeh ET. CRP and the risk of atherosclerotic events. Semin Immunopathol 2009;31:79-94.
10. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested casecontrol study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144:537-47.
11. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Low grade inflammation and coronary heart disease: Prospective study and updated meta-Analyses. Br Med J 2000;321:199-204.
12. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-Aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-42.
13. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-Associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-Aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004;109:837-42.
14. Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: The cardiovascular health study. Circulation 2005;112:25-31.
15. Obradovic M, Sudar E, Zafirovic S, Stanimirovic J, Labudovic-Borovic M, Isenovic ER. Estradiol in vivo induces changes in cardiomyocytes size in obese rats. Angiology 2013. [Epub ahead of print 9 Dec 2013]. doi: 10.1177/0003319713514477.
16. Maravic-Stojkovic V, Lausevic-Vuk LJ, Obradovic M, Jovanovic P, Tanaskovic S, Stojkovic B, et al. Copeptin level after carotid endarterectomy and perioperative stroke. Angiology 2014;65:122-9.
17. Tanaskovic S, Isenovic ER, Radak D. Inflammation as a marker for the prediction of internal carotid artery restenosis following eversion endarterectomy-evidence from clinical studies. Angiology 2011;62:535-42.
18. Pepys MB, Hirschfield GM. C-reactive protein: A critical update. J Clin Invest 2003;111:1805-12.
19. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165-8.
20. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002;105:1890-6.
21. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-Atherosclerosis drugs. Circulation 2001;103:2531-4.
22. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 2004;44:6-11.
23. Hein TW, Singh U, Vasquez-Vivar J, Devaraj S, Kuo L, Jialal I. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis 2009;206:61-8.
24. Valleggi S, Devaraj S, Dasu MR, Jialal I. C-reactive protein adversely alters the protein-protein interaction of the endothelial isoform of nitric oxide synthase. Clin Chem 2010;56: 1345-8.
25. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-9.
26. Venugopal SK, Devaraj S, Jialal I. C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 2003;108:1676-8.
27. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003;107:1783-90.
28. Nickenig G, Harrison DG. The AT(1)-Type angiotensin receptor in oxidative stress and atherogenesis: Part II: AT(1) receptor regulation. Circulation 2002;105:530-6.
29. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001;158:1039-51.
30. Venugopal SK, Devaraj S, Jialal I. Macrophage conditioned medium induces the expression of C-reactive protein in human aortic endothelial cells: Potential for paracrine/autocrine effects. Am J Pathol 2005;166:1265-71.
31. Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, et al. Meta-Analysis of genome-wide association studies in+80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 2011;123:731-8.
32. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-908.
33. Lowe GD, Pepys MB. C-reactive protein and cardiovascular disease: Weighing the evidence. Curr Atheroscler Rep 2006;8: 421-8.
34. Wensley F, Gao P, Burgess S, Kaptoge S, Di Angelantonio E, Shah T, et al. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. Br Med J 2011;342:d548.
35. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. J Am Med Assoc 2009;302: 37-48.
36. Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol 2002;22:1162-7.
37. Zhang YC, Wei JJ, Wang F, Chen MT, Zhang MZ. Elevated levels of oxidized low-density lipoprotein correlate positively with C-reactive protein in patients with acute coronary syndrome. Cell Biochem Biophys 2012;62:365-72.
38. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002;43:1363-79.
39. Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: Clinical significance and therapeutic approaches. Nutrients 2013;5:928-48.
40. Knott TJ, Pease RJ, Powell LM, Wallis SC, Rall SC, Jr., Innerarity TL, et al. Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature 1986;323:734-8.
41. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009;29:431-8.
42. Stocker R. Lipoprotein oxidation: Mechanistic aspects, methodological approaches and clinical relevance. Curr Opin Lipidol 1994;5:422-33.
43. Banach M, Rizzo M, Obradovic M, Montalto G, Rysz J, Mikhailidis DP, et al. PCSK9 inhibition-A novel mechanism to treat lipid disorders? Curr Pharm Des 2013;19:3869-77.
44. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
45. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: Consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2008;51:1512-24.
46. Sudar E, Zafirovic S, Dobutovic BD, Obradovic M, Soskic SS, Jovanovic A, et al. Obesity as a risk factor for cardiovascular diseases: One of the biggest problem in health care today. Life Safety Security 2013;2:5-17.
47. Yoshida H, Kisugi R. Mechanisms of LDL oxidation. Clin Chim Acta 2010;411:1875-82.
48. Grundtman C, Wick G. The autoimmune concept of atherosclerosis. Curr Opin Lipidol 2011;22:327-34.
49. Goyal T, Mitra S, Khaidakov M, Wang X, Singla S, Ding Z, et al. Current concepts of the role of oxidized LDL receptors in atherosclerosis. Curr Atheroscler Rep 2012:150-9.
50. Stanton LW, White RT, Bryant CM, Protter AA, Endemann G. A macrophage Fc receptor for IgG is also a receptor for oxidized low density lipoprotein. J Biol Chem 1992;267:22446-51.
51. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979;76:333-7.
52. Witztum JL, Berliner JA. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol 1998;9:441-8.
53. van Tits L, de Graaf J, Toenhake H, van Heerde W, Stalenhoef A. C-reactive protein and annexin A5 bind to distinct sites of negatively charged phospholipids present in oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 2005;25:717-22.
54. Shih HH, Zhang S, Cao W, Hahn A, Wang J, Paulsen JE, et al. CRP is a novel ligand for the oxidized LDL receptor LOX-1. Am J Physiol Heart Circ Physiol 2009;296:H1643-50.
55. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002;99:13043-8.
56. Fujita Y, Kakino A, Nishimichi N, Yamaguchi S, Sato Y, Machida S, et al. Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem 2009;55:285-94.
57. Hammond DJ, Jr., Singh SK, Thompson JA, Beeler BW, Rusinol AE, Pangburn MK, et al. Identification of acidic pH-dependent ligands of pentameric C-reactive protein. J Biol Chem 2010;285:36235-44.
58. Chang MK, Hartvigsen K, Ryu J, Kim Y, Han KH. The pro-Atherogenic effects of macrophages are reduced upon formation of a complex between C-reactive protein and lysophosphatidylcholine. J Inflamm (Lond) 2012;9:42.
59. Chu CS, Wang YC, Lu LS, Walton B, Yilmaz HR, Huang RY, et al. Electronegative low-density lipoprotein increases C-reactive protein expression in vascular endothelial cells through the LOX-1 receptor. PLoS One 2013;8:e70533.
60. Hein TW, Qamirani E, Ren Y, Xu X, Thengchaisri N, Kuo L. Selective activation of lectin-like oxidized low-density lipoprotein receptor-1 mediates C-reactive protein-evoked endothelial vasodilator dysfunction in coronary arterioles. Circ Res 2014;114: 92-100.
61. Fujita Y, Yamaguchi S, Kakino A, Iwamoto S, Yoshimoto R, Sawamura T. Lectin-like oxidized LDL receptor 1 is involved in CRPmediated complement activation. Clin Chem 2011;57:1398-405.
62. Zhao XQ, Zhang MW, Wang F, Zhao YX, Li JJ, Wang XP, et al. CRP enhances soluble LOX-1 release from macrophages by activating TNF-Alpha converting enzyme. J Lipid Res 2011;52:923-33.
63. Li L, Roumeliotis N, Sawamura T, Renier G. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: Relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. Circ Res 2004;95:877-83.
64. Singh U, Dasu MR, Yancey PG, Afify A, Devaraj S, Jialal I. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 2008;49:1015-23.
65. Eisenhardt SU, Starke J, Thiele JR, Murphy A, Bjorn Stark G, Bassler N, et al. Pentameric CRP attenuates inflammatory effects of mmLDL by inhibiting mmLDL-monocyte interactions. Atherosclerosis 2012;224:384-93.
66. Schwedler SB, Hansen-Hagge T, Reichert M, Schmiedeke D, Schneider R, Galle J, et al. Monomeric C-reactive protein decreases acetylated LDL uptake in human endothelial cells. Clin Chem 2009;55:1728-31.
67. Kobayashi K, Kishi M, Atsumi T, Bertolaccini ML, Makino H, Sakairi N, et al. Circulating oxidized LDL forms complexes with beta2-glycoprotein I: Implication as an atherogenic autoantigen. J Lipid Res 2003;44:716-26.
68. Lin KY, Pan JP, Yang DL, Huang KT, Chang MS, Ding PY, et al. Evidence for inhibition of low density lipoprotein oxidation and cholesterol accumulation by apolipoprotein H (beta2-glycoprotein I). Life Sci 2001;69:707-19.
69. Zhang R, Zhou SJ, Li CJ, Wang XN, Tang YZ, Chen R, et al. C-reactive protein/oxidised low-density lipoprotein/beta2-glycoprotein I complex promotes atherosclerosis in diabetic BALB/c mice via p38mitogen-Activated protein kinase signal pathway. Lipids Health Dis 2013;12:42.
70. Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K, et al. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res 2007;48:768-81.
71. Ueba T, Nomura S, Nishikawa T, Kajiwara M, Yamashita K. Circulating oxidized LDL, measured with FOH1a/DLH3 antibody, is associated with metabolic syndrome and the coronary heart disease risk score in healthy Japanese. Atherosclerosis 2009;203:243-8.
72. Zuliani G, Morieri ML, Volpato S, Vigna GB, Tch CB, Maggio M, et al. Determinants and clinical significance of plasma oxidized LDLs in older individuals. A 9 years follow-up study. Atherosclerosis 2013;226:201-7.
73. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: Five-year prospective results from the Bruneck study. J Am Coll Cardiol 2006;47:2219-28.
74. Langlois MR, Rietzschel ER, De Buyzere ML, De Bacquer D, Bekaert S, Blaton V, et al. Femoral plaques confound the association of circulating oxidized low-density lipoprotein with carotid atherosclerosis in a general population aged 35-55 years: The Asklepios Study. Arterioscler Thromb Vasc Biol 2008;28:1563-8.
75. Park S, Kim M, Paik JK, Jang YJ, Lee SH, Lee JH. Oxidative stress is associated with C-reactive protein in nondiabetic postmenopausal women, independent of obesity and insulin resistance. Clin Endocrinol (Oxf) 2013;79:65-70.
76. van Tits LJ, van Himbergen TM, Lemmers HL, de Graaf J, Stalenhoef AF. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2006;185:307-12.
77. Rodenburg J, Vissers MN, Wiegman A, Miller ER, Ridker PM, Witztum JL, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: Effect of pravastatin. J Am Coll Cardiol 2006;47:1803-10.
78. Holvoet P, Harris TB, Tracy RP, Verhamme P, Newman AB, Rubin SM, et al. Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: Findings from the Health, Aging, and Body Composition study. Arterioscler Thromb Vasc Biol 2003;23:1444-8.
79. Fujii H, Shimizu M, Ino H, Yamaguchi M, Terai H, Mabuchi H, et al. Oxidative stress correlates with left ventricular volume after acute myocardial infarction. Jpn Heart J 2002;43:203-9.
80. Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, et al. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol 2009;53:2186-96.
81. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998;98:1487-94.
82. Johnston N, Jernberg T, Lagerqvist B, Siegbahn A, Wallentin L. Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease. Int J Cardiol 2006;113:167-73.
83. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005;353:46-57.
84. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004;110:1406-12.
85. Wu T, Willett WC, Rifai N, Shai I, Manson JE, Rimm EB. Is plasma oxidized low-density lipoprotein, measured with the widely used antibody 4E6, an independent predictor of coronary heart disease among U.S. men and women? J Am Coll Cardiol 2006;48:973-9.
86. Meisinger C, Baumert J, Khuseyinova N, Loewel H, Koenig W. Plasma oxidized low-density lipoprotein, a strong predictor for acute coronary heart disease events in apparently healthy, middle-Aged men from the general population. Circulation 2005;112:651-7.
87. Huang Y, Wu Y, Hu Y. Correlation of oxidized low-density lipoprotein and C-reactive protein in patients with coronary artery disease. Cell Biochem Biophys 2013;65:285-6.
88. Tsimikas S, Willerson JT, Ridker PM. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 2006;47:C19-31.